Stenotrophomonas maltophilia: Complicating treatment of ESBL UTI

• Main Authors: Simit Kumar, Maitreyi Bandyopadhyay, Mitali Chatterjee, Parthajit Banerjee, Sumon Poddar, Debarati Banerjee
• Format: Article
• Language: English
• Published: Wolters Kluwer Medknow Publications 2015-01-01
• Series: Advanced Biomedical Research
• Subjects: Antimicrobial sensitivity; Stenotrophomonas maltophilia; urinary tract infection
• Online Access: http://www.advbiores.net/article.asp?issn=2277-9175;year=2015;volume=4;issue=1;spage=36;epage=36;aulast=Kumar

Stenotrophomonas maltophilia (S. maltophilia) is a gram-negative bacillus emerging as an opportunistic, nosocomial pathogen associated with a high mortality rate. The organism has been shown to survive several biocides used in the hospital setting. Hospital water sources can serve as a reservoir for S. maltophilia. The transmission of S. maltophilia to susceptible individuals may occur through direct contact with the source or through the hands of health care personnel. S. maltophilia is usually resistant to third-generation cephalosporins, aminoglycosides and antipseudomonal penicillins. These microorganisms are intrinsically resistant to carbapenems, and exposure to these agents has been linked to selection of S. maltophilia. There have also been reports of the organism developing resistance to trimethoprim-sulfamethoxazole (TMP-SMX), which was initially considered as the drug of choice for S. maltophillia infections. We describe a case of nosocomial urinary tract infection (UTI) due to S. maltophilia in a diabetic patient, which the patient developed during treatment with meropenem for UTI due to Klebsiella pneumonia that was resistant to TMP-SMX.